Mereo BioPharma Group (MREO) Income Annual - Discounting Cash Flows
Mereo BioPharma Group plc
MREO (NASDAQ)

* (except for per share items) of USD
Period Ending: LTM
(Last Twelve Months)
2023
12-31
2022
12-31
2021
12-31
2020
12-31
2019
12-31
2018
12-31
2017
12-31
2016
12-31
Report Filing 2024-03-27 2023-03-28 2022-03-31 2021-03-31 2020-06-15 2019-04-29 2017-12-31 2016-12-31
Revenue
10.0 1.51 36.5 0.39 -0.12 0.00 -3.29 0.00
Cost of Revenue
2.57 0.94 17.9 16.3 23.6 22.7 34.6 24.6
Gross Profit
7.43 0.57 18.6 -16.0 -23.7 -22.7 -37.9 -24.6
Operating Expenses
35.8 44.1 39.5 21.6 15.8 12.5 7.41 11.6
Research & Development
17.4 25.0 23.6 -16.3 -23.6 22.7 34.6 24.6
Selling, General and Administrative
18.4 19.5 15.9 21.2 15.9 12.5 10.7 11.6
Other Operating Expenses
0.00 -0.36 0.00 16.7 23.5 -22.7 -37.9 -24.6
Operating Income
-28.4 -43.6 -20.9 -37.6 -39.5 -35.2 -45.3 -36.2
Net Non-Operating Interest
-0.75 -2.66 -4.00 -6.34 -3.12 -2.05 -0.26 0.02
Interest Income
2.13 0.70 0.00 0.04 0.38 0.31 0.83 0.20
Interest Expense
2.88 3.36 4.00 6.38 3.50 2.36 1.09 0.18
Equity & Other Income/(Expense)
-0.83 10.1 39.2 -123 1.52 -0.04 -1.38 2.44
Income Before Tax
-30.0 -36.1 14.2 -166 -41.1 -37.3 -47.0 -33.7
Income Tax Expense
-0.53 -1.90 1.52 -2.82 -6.27 -5.28 -8.15 -5.33
Income Attributable to Non-Controlling Interest
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Income
-29.5 -34.2 12.7 -164 -34.8 -32.0 -38.8 -28.4
Depreciation and Amortization
1.06 1.51 0.87 0.04 1.95 0.04 0.04 0.03
EBITDA
-27.4 -42.1 -20.1 -37.5 -37.6 -35.2 -45.3 -36.1
Earnings Per Share (EPS)
-220.0 -350.1 149.9 -3,301 -2,581 -2,871 -3,801 -3,911
Diluted Earnings Per Share
-220.0 -350.1 149.9 -3,301 -2,581 -2,871 -3,801 -3,911
Weighted Average Shares Outstanding
659 603 584 339 89.3 71.1 69.0 44.8
Diluted Weighted Average Shares Outstanding
659 603 584 339 89.4 71.1 69.0 44.8
discounting cash flows home logo

Discounting Cash Flows

Are you finding our services helpful? Review us on trustpilot logo Trustpilot
Have a question? Contact us